We are live on ! Find out more
CTXR icon

Citius Pharmaceuticals

32 hedge funds and large institutions have $1.48M invested in Citius Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

84% more capital inflows, than outflows

Capital inflows: $512K | Capital outflows: $279K

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

11% more call options, than puts

Call options by funds: $78K | Put options by funds: $70K

10% more funds holding

Funds holding: 29 → 32 (+3)

1.36% more ownership

Funds ownership: 7.41% → 8.77% (+1.4%)

Holders
32
Holders Change
+3
Holders Change %
+10.34%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
7
Reduced
6
Closed
5
Calls
$78K
Puts
$70K
Net Calls
+$8K
Net Calls Change
-$5K

CTXR Hedge Fund Activity: Q2 2025 in Review

32 of the 7,630 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2025, worth a combined $1.48M — up 56% from $949K a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CTXR positions and 5 closed out — a net gain of 3 holders — while 7 added to existing stakes and 6 trimmed.

The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $168K. The largest seller was Vanguard Group, cutting an estimated $163K.

  • 32 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2025, up from 29 in Q1 2025.
  • Funds reported $1.48M of Citius Pharmaceuticals stock for Q2 2025, up 56% quarter-over-quarter.
  • 8 funds opened new Citius Pharmaceuticals positions in Q2 2025 and 5 closed out, a net change of +3 holders.
  • The largest Citius Pharmaceuticals buyer in Q2 2025 was Cambridge Investment Research Advisors, an estimated $168K added.
  • The largest Citius Pharmaceuticals seller in Q2 2025 was Vanguard Group, an estimated $163K sold.

Based on aggregated 13F filings for Q2 2025.